How Drug Price Negotiation Is Reshaping Clinical Trial Pipelines
Feb 24, 2026
20:32
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Health Affairs' Rob Lott interviews So-Yeon Kang of Georgetown University about her recent paper exploring trends in biopharmaceutical clinical trials after The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs.
Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast for everyone.
